Welcome to The Game-Changing Paradigm Shift in Rescue Therapy for Asthma

Embark on a journey of professional growth within our educational hub of accredited education, and a thriving community to aid you in staying at the forefront of the paradigm shift in asthma care.

This educational curriculum is focused on the management of poorly-controlled asthma and will be designed to improve clinician awareness, knowledge, and competence and ultimately change clinical practice. The target audience includes pulmonologists and allergists/immunologists practicing in various regions across the United States. This may also interest primary care clinicians, and pulmonology advanced practice providers, and nurses.

Curriculum Goals

The goals of this curriculum are three-fold:

Increase awareness of the paradigm shift to replace as-needed short-acting-beta2 agonists (SABAs) with as-needed inhaled corticosteroid (ICS)-SABA or ICS-formoterol combination inhalers for acute asthma symptoms.

Improve knowledge and competence regarding the use of a combination of ICS-SABA or ICS-formoterol as needed for acute symptoms in patients with poorly-controlled asthma.

Ultimately, improve the clinical practice of pulmonologists, allergists, and other members of the referring care team, including primary care clinicians, pulmonology advanced practice providers, and nurses.

Objectives

This proposed initiative will focus on the following educational objectives:

l

Identify patients with asthma whose symptoms are not well controlled based on clinical and/or spirometric criteria.

Distinguish which asthma patients may benefit from rescue short-acting beta agonist (SABA) alone compared with those who may benefit from using anti-inflammatory reliever (AIR) therapy as needed for acute symptoms of asthma based on GINA 2023 recommendations.

Determine clinical scenarios where AIR-only therapy or maintenance and reliever therapy (MART) with inhaled corticosteroid-formoterol may be used to improve outcomes in patients with symptomatic asthma.

Identify and develop approaches to overcome barriers to integrating AIR or MART with an ICS-formoterol to the regimen for appropriate patients with symptomatic asthma.

Ready to embrace a game-changing approach to asthma rescue therapy?

Join the Evolving Community and be at the forefront of a paradigm shift to aid your patients.

Name(Required)
Email(Required)
Please let us know what's on your mind. Have a question for us? Ask away.
This field is for validation purposes and should be left unchanged.

Accreditation

In support of improving patient care, this activity has been planned and implemented by Dannemiller and WipeDiseases. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
Dannemiller designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists
Dannemiller has assigned 1 contact hour (1 CEUs) of continuing pharmacy education credit to this activity.

Nurses
Dannemiller designates this educational activity for 1 CE contact hours.

Physician Assistants
Dannemiller has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for a maximum of 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Commercial Support
Supported by an educational grant from AstraZeneca.

Off-label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer
The content and views presented in this educational activity are those of the authors and do not
necessarily reflect those of Dannemiller, WipeDiseases, or AstraZeneca. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject.

 

This educational activity has been a joint collaboration between: